Significance Statement {#s5}
======================

The importance of early detection and intervention in psychosis has renewed interest in subtle psychopathology beyond positive and negative symptoms but also in the search of biological markers of the disease. In this vein, the determination of some initial changes in cardiovascular markers, including adhesion molecules (VCAM-1 and E-Selectin) and adiponectin, have interesting potential as biological markers and potential risk/protective factors. In this study, we have found evidence of subtle but concomitant alterations of classical cardiovascular and metabolic risk factors in a cohort of patients at the first onset of positive psychotic symptoms and 6 months after. In addition, alterations in adiponectin plasma levels could be a good clinical index, reflecting the grade of severity of the symptomatology, and could be affected by the balance between pro-/antiinflammatory mediators. Our results support the need of integrating CV health care very early in the first episode of psychosis.

Introduction {#s6}
============

Increasing evidence supports the potential benefits of early intervention to enable disease prevention and to improve prognosis in psychiatric disorders, this being particularly important in schizophrenia (SZ) ([@CIT0036]; [@CIT0052]). To consolidate this intervention, a deeper scientific effort is needed to properly identify and characterize the early phase of the disease ([@CIT0013]). The First Episode of Psychosis (FEP) is classically considered the onset of the disease or, at least, the moment of the first presentation of psychotic symptoms, typically during late adolescent or early adult years. At this initial stage, the number of confounding variables produced by chronicity and medication is lower and consequently, the search for risk/protective biomarkers directly related to the etiopathogenesis of the disease is favored ([@CIT0017]).

Chronic disease-induced lifestyle and the long-term use of antipsychotic medication are factors directly related to the appearance of comorbid metabolic disorders and cardiovascular (CV) alterations in the symptomatology of SZ, which are considered one of the main causes of premature death ([@CIT0044]). Specifically, chronic use of antipsychotics can induce metabolic alterations (weight gain, obesity, diabetes, hyperglycemia, dyslipidemia, and metabolic syndrome) directly related to an increased risk of suffering CV pathologies ([@CIT0014]; [@CIT0010]). However, even at the early stage of illness around FEP, metabolic abnormalities related to the first year of antipsychotic medication have been reported ([@CIT0038]) as well as increased CV risk in patients with first-episode SZ spectrum disorders ([@CIT0011]). In a more recent prospective and naturalistic study ([@CIT0008]), antipsychotic polypharmacy (and other factors) have been related to the extremely high risk for patients at early phases of SZ and other psychotic disorders of developing CV comorbidity, as well as the rapid worsening of the metabolic profile during the first 2 years.

The effects of antipsychotic drugs seem to be more pronounced at the onset of treatment (as soon as 8--12 weeks after initiation) in young antipsychotic-naive patients after FEP, including body weight gain and body mass index (BMI) increase ([@CIT0042]). However, there is growing evidence regarding the existence of subtle metabolic/CV alterations in drug-naïve psychotic populations or FEP subjects exposed to antipsychotics for a short, known period (2--4 weeks), suggesting the role of alternative susceptibility factors and premature etiopathogenic mechanisms not exclusively dependent on unhealthy lifestyle or antipsychotic medication. Thus, some authors have reported that drug-naïve, FEP patients are more insulin resistant (as assessed by the homeostatic model assessment index) compared with healthy controls ([@CIT0039]). Lipid metabolism and abnormal QTc interval prolongation could also be affected in drug-naïve FEP patients ([@CIT0055], [@CIT0056]). The existence of concomitant individual risk factors in some FEP subjects such as subtle changes in hypertension, hypertriglyceridemia, abdominal obesity, and hyperglycemia without higher baseline metabolic syndrome prevalence compared with the general population of similar age needs to be further corroborated ([@CIT0015]).

However, some discrepancy exists, and some studies did not find increased metabolic syndrome prevalence in *naïve* patients with a first episode of nonaffective psychosis compared with matched normal population ([@CIT0021]). Other authors have found similar results reporting no signs of insulin resistance and dyslipidemia in drug-naïve FEP patients ([@CIT0045]; [@CIT0012]). Some meta-analysis concluded that there is no difference in CV risk assessed by weight gain or classical metabolic indices between individuals with an untreated FEP and matched controls ([@CIT0016]).

These discrepant results suggest the need to search for novel metabolic alterations at a molecular level for the identification and early intervention of metabolic and CV risk in drug-naïve psychosis patients or FEP subjects exposed to antipsychotics for a short, known period of time. The search for systemic biomarkers for the early identification of individuals likely to suffer metabolic/CV alterations or to evaluate their future response to antipsychotics is continuously growing and crosslinks with other disciplines, as is the study of innate immunity/inflammation.

Inflammation is receiving special attention as an important component in the physiopathology of metabolic and CV disorders. Certain inflammatory mediators have been considered as potential biomarkers for these pathologies ([@CIT0018]). In fact, there are consolidated (i.e., high-sensitivity C-reactive protein levels, cytokines) and emerging inflammatory markers for CV risk ([@CIT0030]) that need to be further characterized, considering the evidence for elevated systemic inflammation in patients with FEP and SZ ([@CIT0019], [@CIT0020]; [@CIT0029]).

Candidates to survey in FEP are cell adhesion molecules, including VCAM-1 and the selectins (P, E, and L), inflammatory markers implicated in the etiology and physiopathology of atherosclerosis, and therefore metabolic syndrome and CV disease ([@CIT0009]). Recently abnormal VCAM-1 and selectin levels have been reported in SZ, being suggested as biomarkers for endothelial dysfunction ([@CIT0033]). The capacity of atypical antipsychotics such as risperidone to upregulate V-CAM and selectin levels contributing to worsening endothelial function in diabetic rats has been also reported ([@CIT0001]). Another relevant mediator is the adipocytokine adiponectin, a master regulator of glucose metabolism and fatty acid oxidation and currently considered as a link between the inflammatory response and lipid metabolism. Reduced levels of adiponectin have been related to metabolic disorders such as obesity, insulin resistance, and type 2 diabetes ([@CIT0046]). Furthermore, several authors have reported decreased adiponectin levels also in mental disorders ([@CIT0054]).

Based on this background, we aimed to investigate the state of the inflammatory-related mediators VCAM-1, E-selectin, and adiponectin, considered to be putative CV risk/protective risk factors, in plasma samples of FEP patients from the Flamm-PEPs study. This is a multicenter, longitudinal, naturalistic, follow-up study designed to evaluate systemic inflammatory alterations inside the Spanish national network for mental health research ([@CIT0019], [@CIT0020]). In this study, we applied previously validated robust multiple linear regression models to further analyze the change in every biological marker in relation to clinical characteristics classically related to increased metabolic and CV risk, confounding factors as diverse antipsychotic medication, and pro-/antiinflammatory mediators previously described in these same control, baseline, and 6-month follow-up FEP patients.

Materials and Methods {#s7}
=====================

Subjects {#s8}
--------

We recruited a total of 119 FEP subjects during the first year after their FEP according to the DSM-IV criteria ([@CIT0003]) in 5 tertiary hospitals in Spain as well as 108 gender-, ethnicity-, and age-matched controls between September 2010 and June 2011. From the initial sample, 85 FEP subjects were followed for the next 6 months (maximum 12 months after inclusion). In adults, the diagnosis was established by expert clinicians using the semistructured diagnostic interview designed to assess current and past psychopathology and personality disorders, according to DSM-IV criteria (SCID-I and II). For subjects \<18 years old, diagnosis was made using the Spanish translation of the Kiddie-Schedule for Affective Disorders and SZ, Present and Lifetime Version ([@CIT0051]). The duration of untreated psychosis (DUP) was defined as the number of days elapsed between the onset of positive psychotic symptoms (the first week with the PANSS items P1, P3, P5, P6, or G9 score ≥4) and the first appropriate treatment for psychosis. Being a naturalistic study, there were no specific guidelines for treatments, so patients received antipsychotic treatment based on the clinician's choice. Dosing, co-medications, or treatment changes were based on clinical necessity. Following the inclusion/exclusion criteria, treatment with antipsychotics did not exceed 12 months at study entry ([@CIT0007]).

Multiple sources, including medical records and interviews with relatives, were used to ascertain the length of this period. The initial number of recruited subjects, the final number of those to fulfill both clinical and the whole analytical study, and site recruitment details are shown in the supplementary information. This cohort was considered as the FEP baseline group. FEP subjects were followed up for 6 months (maximum 12 months after inclusion), and this cohort was considered as the FEP follow-up group.

Baseline and follow-up demographic details of patients and controls involved in the study are detailed in [Table 1](#T1){ref-type="table"}. In brief, mean age was 24.21±6.08 years, with a greater percentage of males (70.6%). To ensure diagnosis stability, clinical evaluations were repeated after 6 months of the patient's inclusion. Tto not exclude early-onset psychotic patients, there was a broad age of inclusion allowed. The inclusion criteria for patients were: (1) age between 7 and 35 years at the time of first evaluation; (2) presence of psychotic symptoms of \<12 months' duration; (3) ability to speak Spanish correctly; and (4) signed the informed consent. The exclusion criteria for patients were: (1) mental retardation per the DSM-IV criteria, including not only an IQ \<70 but also impaired functioning; (2) history of head trauma with loss of consciousness; and (3) organic disease with mental repercussions.

###### 

Demographic and Clinical Characteristics

                                             Patients Baseline (b)   Patients Follow- up (f)   p value (b-f)   Controls ( c)   P value (b-c)   P value (f-c)
  ------------------------------------------ ----------------------- ------------------------- --------------- --------------- --------------- ---------------
  **N**                                      85                      85                                        106                             
  **Age-years**                              24,21(6,028)            25,21 (6,028)                             25,43(6,428)    0,21            
  **Sex- nº(%**)                                                                                                                               
  **Male**                                   60(70,6)                \-                                        70(66,0)        0,503           
  **Female**                                 25(29,4)                \-                                        36(34,0)                        
  **Age of psychosis onset**                 24,37(5,93)             \-                                                                        
  **Socioeconomic Status**                                                                                                                     
  **High**                                   16(18,8)                \-                                        14(13,2)        0,01            
  **Medium-High**                            7(8,2)                  \-                                        17(16,0)                        
  **Medium**                                 30(35,3)\*              \-                                        54(50,9)                        
  **Medium-Low**                             24(28,2)                \-                                        19(17,9)                        
  **Low**                                    8(9,4)\*                \-                                        2(1,9)                          
  **Ethnic group**                                                                                                                             
  **Caucasian**                              79(92,9)                \-                                        96(90,6)        0,344           
  **Gipsy**                                  1(1,2)                  \-                                        0(0,0)                          
  **Maghrebian**                             1(1,2)                  \-                                        2(1,9)                          
  **Asian**                                  1(1,2)                  \-                                        0(0,0)                          
  **Caribbean**                              1(1,2)                  \-                                        0(0,0)                          
  **Hispanic**                               2(2,4)                  \-                                        6(5,7)                          
  **Others**                                 0 (0,0)                 \-                                        2(1,9)                          
  **Diagnosis nº(%**)                                                                                                                          
  **Affective Psychosis\***                  17(20)                  17(20)                    0,026           \-                              
  **Non-affective Psychosis**                68(80)                  62(72,9)                                  \-                              
  **Drugs Psychosis**                        0(0,0)                  0(0,0)                                    \-                              
  **No psychosis**                           0(0,0)                  6(7,1)                                    \-                              
  **Psychopathology score**                                                                                                                    
  **PANSS POSITIVE**                         10,67(5,379)            8,01(5,032)               \<0,001         \-                              
  **PANSS NEGATIVE**                         14,58(6,27)             11,76(8,149)              0,001           \-                              
  **PANSS GENERAL**                          26,47(9,75)             20,524(11,9)              \<0,001         \-                              
  **PANSS TOTAL**                            51,72(19,23)            40,29(23,6)               \<0,001         \-                              
  **YOUNG**                                  1,45(3,25)              1,39(3,5)                 0,711           \-                              
  **Montgomery-Asberg**                      6,51(6,52)              5,75(6,71)                0,096           \-                              
  **Global functioning score (GAF**)         68,60(13,88)            72,08(17,22)              0,005           \-                              
  **DUP**                                    68,58(77,29)                                                      \-                              
  **Antipsycohotic medications - n(%**)                                                                                                        
  **None**                                   17(20,0)                21(25,9)                                  \-                              
  **Risperidone**                            30(35,3)                21(25,9)                                  \-                              
  **Aripiprazole**                           9(10,6)                 15(18,5)                                  \-                              
  **Olanzapine**                             9(10,6)                 6(7,4)                                    \-                              
  **Quetiapine**                             6(7,1)                  5(6,2)                                    \-                              
  **Clozapine**                              5(5,9)                  6(7,4)                                    \-                              
  **Ziprasidone**                            2(2,4)                  2(2,5)                                    \-                              
  **Paliperidone**                           7(8,2)                  5(6,2)                                    \-                              
  **DDD**                                    282,19(253,04)          298,06(303,16)            0,903           \-                              
  **Lithium n(%**)                           8(9,4)                  7(8,2)                    0,824           \-                              
  **Body mass index**                        24,83(3,92)\*           24,65(5,73)               0,06            23,14(3,16)     0,002           0,003
  **Tobacco use per month, n cigarettes**    238,9(259,08)\*         241,98(254,1)             0,881           45,38(119,3)    \<0,001         \<0,001
  **Cotinine, ng/ml**                        86,73(84,46)            97,28(84,50)              0,192           26,28(49,31)    \<0,001         \<0,001
  **Cotinine, ng/ml**                                                                                                                          
  **minor PC n(%**)                          31(39,7)                29(34,9)                  0,529           60(70,6)        \<0,001         \<0,001
  **major PC n(%**)                          47(60,3)                54(65,1)                                  25(29,4)                        
  **CANNABIS use n(%**)                      18(21,2)\*              4(5,1)                    0,003           14(15,9)        0,372           0,325
  **CANNABIS use per month, n cigarettes**   4,71(19,36)             1,09(6,37)                0,092           1,15(6,36)      0,657           0,345

**DUP:** duration of untreated psychosis.

**DDD:** Defined daily dose of chlorpromazine equivalents (mg).

\* Affective psycho.sis includes DSM-IV diagnosis of unipolar depression or bipolar disorder with psychotic features and schizoaffective disorder.

Healthy controls were selected from the same geographic areas. The inclusion criteria for controls were: (1) same gender as patients; (2) similar age (±10%) as patients; (3) similar socioeconomic status as patients, measured by the Hollingshead-Redlich scale (±1 level); (4) no past or present psychiatric disorder per DSM-IV criteria; (5) ability to speak Spanish correctly; and (6) signed the informed consent. The exclusion criteria for controls were: (1) mental retardation according to DSM-IV criteria (American Psychiatric Association (Washington), 1994) including not only an IQ \<70 but also impaired functioning; (2) history of head trauma with loss of consciousness; (3) organic disease with mental repercussions; and (4) history of psychotic disorder among first-degree relatives.

Clinical assessment of patients and controls included a complete medical history and physical examination, laboratory tests (thyroid function, liver function, renal function, electrolyte levels, complete blood cell count, and urinalysis), and electrocardiogram. Anthropometric measures were assessed: weight, height, and BMI(weight in kg/height^2^). A complete description of the clinical protocol has been published elsewhere ([@CIT0008]). The exclusion criteria were ongoing infections, fever, allergies, or the presence of other serious medical conditions (autoimmune, cardiac, pulmonary, endocrine, chronic infectious diseases, neoplasms). Having designed a real-life patient, naturalistic study, substance use was not an exclusion criterion. Neither the FEP patients nor the healthy control subjects received immunosuppressive drugs or vaccinations for at least 6 months prior to inclusion in the study or antiinflammatory analgesics the 2 days prior to the blood sample.

The study was approved by the ethics committees of the 5 participant hospitals. The subjects participated after receiving a full explanation of the study and providing written, informed consent in accordance with the Declaration of Helsinki II.

Specimen Collection and Preparation {#s9}
-----------------------------------

Venous blood samples (10 mL) were collected by nursing personnel in polypropylene EDTA-containing tubes in the morning (between 8:00 and 10:00 [am]{.smallcaps}) after fasting overnight. All the sample collection and preparation protocols were approved by the technical committee of the Flamm-PEPs study (available on [www.cibersam.es](http://www.cibersam.es)). The fresh blood samples were maintained at 4ºC until preparation after approximately 1 hour.

Blood tubes were centrifuged (641xg for 10 minutes, 4ºC). The resultant plasma samples were carefully collected and stored at -80ºC until further action was required.

Biochemical Determinations in Plasma {#s10}
------------------------------------

VCAM-1, E-Selectin, and adiponectin levels were measured by enzyme-linked immunosorbent assay following the manufacturer's instructions. Plasma samples were diluted 1:200 for VCAM-1 and 1:100 for E-Selectin determinations with the assay diluent included in the commercial kits (RayBio). The sensitivity of the assay for VCAM-1 was 0.3 ng/mL and 30 pg/mL for E-Selectin; intra- and inter-assay CVs were \<10% and \<12%, respectively, in both kits. Plasma samples were diluted 1:5151 for determinations of total and high-molecular adiponectin fraction levels (Alpco). The detection limit was 0.019 ng/mL; intra- and inter-assay CVs were 5.4% and 5.0%, respectively. The absorbance measurements were determinate in the multi-mode plate reader Synergy 2 (BioTek).

Metabolic and CV risk parameter data of the subjects included in our study were already published as a part of the PEPs Project, which recruited 335 FEP subjects and 253 matched healthy controls ([@CIT0008]). Briefly, in all the participating sites, blood glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein cholesterol, and triglycerides were directly analyzed by enzymatic procedures with an Automatic Chemical Analyzer. Glycated hemoglobin was analyzed by high-performance liquid chromatography. The reference values at each site were recorded in a common database called GIDSAM, where individual values were homogenized and included ([@CIT0006]).

Proinflammatory/antiinflammatory parameters data of the subjects included in our study were previously published ([@CIT0019], [@CIT0020]).

Statistical Analysis {#s11}
--------------------

Differences between demographic, clinical, and biological markers for patients and controls were assessed using chi-square, *t* test, nonparametric Mann-Whitney U or Wilcoxon tests according to the distribution and scales of the variables. To calculate the association between the level of biological markers and FEP, multiple linear regression models were used in which we controlled for potential confounders (age, gender, CV history, cannabis, and tobacco use per month). Multiple linear regression analysis was used to analyze the change in each biological marker depending on the change in demographic (gender, age), clinical variables (CV history, lithium, DUP, GAF), antipsychotic medication (defined daily dose \[DDD\] and types), and cannabis and tobacco (cotinine). Correlations were analyzed to evaluate the association between biological markers and pro-/antiinflammatory parameters.

Results {#s12}
=======

Demographic and Clinical Features {#s13}
---------------------------------

The demographic and clinical characteristics of the FEP patients and the healthy control group are presented in [Table 1](#T1){ref-type="table"} and can be also found in a previous study evaluating the status of systemic inflammation in the same groups of control and FEP subjects ([@CIT0019], [@CIT0020]). Both baseline and follow-up FEP patients differed in BMI compared with matched controls (BMI, respectively; 24.83±3.92; 24.65±5.73 vs 23.14±3.16, *P*=.002; *P*=.003). Another important characteristic of our cohorts is the different type of antipsychotic medication used. In baseline FEP conditions, only 9 patients (10.6%) were treated with olanzapine and 6 (7.1%) with quetiapine. In the follow-up group, 6 (7.4%) received olanzapine and 5 (6.2%) quetiapine. PANSS and GAF clinical scales showed significantly less severe symptomatology in the follow-up group compared with baseline FEP condition.

Metabolic and CV Alterations in FEP Baseline and Follow-Up Groups {#s14}
-----------------------------------------------------------------

Firstly, we explored the general state of typical metabolic and CV parameters in the 3 groups of subjects studied. Bivariate analysis found a significantly higher basal triglyceride levels and abdominal perimeter in the FEP baseline group compared with controls, while HDL cholesterol values appeared lower in the pathological baseline group ([Table 2](#T2){ref-type="table"}). In the follow-up group, all these alterations remained present, and a significant increase in glycosylated hemoglobin was also found ([Table 2](#T2){ref-type="table"}). Baseline and follow-up groups only differed in glycosylated hemoglobin levels that were lower in baseline group ([Table 2](#T2){ref-type="table"}).

###### 

Classical cardiovacular and metabolic risk biomarkers in Control and FEP's baseline and follow-up Patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                      Baseline        Follow-up   Case Baseline - Case Follow-up                                                                                                                                                        
  ----------------------------------- --------------- ----------- -------------------------------- --------- ------- ----------------- --------------- ---------- ------- ----------------- --------------- --------- --------------- --------- ------- -----------------
  **BASAL_Glucose**                   **84,49**\      7,97        **84,49**\                       11,10     -0,27   0,787\*\*         **88,26**\      15,51      -0,89   0,373^&^          **84,40**\      11,35     **88,26**\      15,51     -1,68   0,093^&^
                                      *(83*)                      *(96*)                                                               *(70*)                                               *(82*)                    *(70*)                            

  **BASAL_glycosylated hemoglobin**   **5,09**\       0,32        **5,08**\                        0,26      -0,28   0,782\*\*         **5,23**\       0,32       -2,76   **0,006** ^&^     **5,08**\       0,26      **5,23**\       0,32      -4,13   **\<0,001** ^&^
                                      *(79*)                      *(90*)                                                               *(71*)                                               *(78*)                    *(71*)                            

  **BASAL_Triglycerides**             **75,81**\      35,20       **99,24**\                       57,10     -3,37   **0,001**\*\*     **104,21**\     52,59      -3,96   **\<0,001** ^&^   **99,28**\      57,56     **104,21**\     52,59     -1,23   0,220^&^
                                      *(80*)                      *(95*)                                                               *(73*)                                               *(81*)                    *(73*)                            

  **BASAL_Cholesterol**               **170,73**\     39,38       **170,09**\                      36,55     -0,36   0,722\*           **167,26**\     31,18      -0,60   0,547\*           **168,60**\     37,35     **167,26**\     31,18     -0,36   0,724\*
                                      *(82*)                      *(96*)                                                               *(73*)                                               *(82*)                    *(73*)                            

  **BASAL_Cholesterol_HDL**           **54,79**\      12,49       **47,09**\                       13,69     -4,36   **\<0,001**\*\*   **44,78**\      13,36      -5,02   **\<0,001** ^&^   **47,09**\      13,16     **44,78**\      13,36     -1,68   0,093^&^
                                      *(82*)                      *(95*)                                                               *(73*)                                               *(81*)                    *(73*)                            

  **BASAL_Cholesterol_LDL**           **100,42**\     32,74       **102,71**\                      29,72     0,14    0,892\*           **101,90**\     26,66      0,31    0,759\*           **101,10**\     29,84     **101,90**\     26,66     -0,63   0,529\*
                                      *(83*)                      *(94*)                                                               *(73*)                                               *(80*)                    *(73*)                            

  **BASAL_SAP**                       **122,24**\     15,53       **120,13**\                      12,91     -1,09   0,277\*\*         **119,38**\     13,01      -1,15   0,252\*           **120,68**\     12,63     **119,38**\     13,01     1,10    0,277^&^
                                      *(82*)                      *(94*)                                                               *(72*)                                               *(80*)                    *(72*)                            

  **BASAL_DAP**                       **71,04**\      8,20        **71,41**\                       9,05      -0,19   0,847\*\*         **71,28**\      9,79       0,17    0,868\*           **71,51**\      9,08      **71,28**\      9,79      0,30    0,766\*
                                      *(82*)                      *(94*)                                                               *(72*)                                               *(80*)                    *(72*)                            

  **BASAL_ABDOMINAL perimeter**       **84,32**\      8,75        **89,64**\                       10,57     3,45    **\<0,001**\*     **90,42**\      9,42       4,13    **\<0,001**\*     **89,71**\      10,71     **90,42**\      9,42      -0,89   0,376\*
                                      *(79*)                      *(92*)                                                               *(72*)                                               *(78*)                    *(72*)                            

  **VCAM-1**                          **329,24**\     194,53      **278,29**\                      161,31    -2,19   **0,029**\*\*     **307,45**\     212,85     -1,42   0,157\*\*         **283,19**\     159,85    **301,69**\     207,89    -0,25   0,801^&^
                                      *(85*)                      *(99*)                                                               *(82*)                                               *(68*)                    *(81*)                            

  **E-Selectin**                      **10.949,2**\   7.580,2     **13.723,3**\                    8.598,4   -2,47   **0,014**\*\*     **10.270,5**\   6.857,06   -0,31   0,759\*\*         **13.750,0**\   9.040,8   **10.128,7**\   6.777,7   -3,76   **0,000** ^&^
                                      *(84*)                      *(94*)                                                               *(82*)                                               *(65*)                    *(81*)                            

  **Adiponectin HMW**                 **3,55**\       2,40        **3,13**\                        \         -1,20   0,229\*\*         **2,68**\       1,66       -2,86   **0,004**\*\*     **2,92**\       1,67      **2,70**\       1,6623    -2,17   **0,030** ^&^
                                      *(76*)                      *(84*)                           1,85                                *(82*)                                               *(68*)                    *(81*)                            

  **Adiponectin total**               **6,09**\       2,51        **5,78**\                        2,46      -0,82   0,409\*\*         **4,29**\       1,57       -4,13   **\<0,001**\*\*   **5,66**\       2,51      **4,34**\       1,54      -4,35   **0,000** ^&^
                                      *(37*)                      *(44*)                                                               *(47*)                                               *(35*)                    *(81*)                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(N)= number of subjects for each determination

\* parametric t-student test.

\*\* non-parametric U-Mann Whitney test.

& non-parametric Wilcoxon test.

Novel CV Risk/Protective Factors in FEP Baseline and Follow-Up Groups {#s15}
---------------------------------------------------------------------

Next, we aimed to evaluate whether there were alterations in the plasma levels of the putative metabolic and CV risk (VCAM-1, E-Selectin) and protective (adiponectin, both in its high molecular weight \[HMW\] and total) markers between control, baseline, and follow-up groups.

Bivariate analysis showed that VCAM-1 levels were significantly lower in the baseline group compared with the control group ([Table 2](#T2){ref-type="table"}; [Figure 1A](#F1){ref-type="fig"}). This effect was partly due to an absence in the follow-up group, returning to values near control levels ([Table 2](#T2){ref-type="table"}; [Figure 1A](#F1){ref-type="fig"}). In the case of the other adhesion molecule E-selectin, the pattern was the opposite. The baseline group's E-selectin plasma levels were higher than control subjects ([Table 2](#T2){ref-type="table"}; [Figure 1B](#F1){ref-type="fig"}). This effect was significantly reversed in the follow-up conditions, returning to control levels ([Table 2](#T2){ref-type="table"}; [Figure 1B](#F1){ref-type="fig"}).

![Plasma levels of cardiovascular (CV) factors between first episode of psychosis (FEP) and controls. Mean differences (SD) on VCAM-1 (A), E-Selectin (B), adiponectin high (molecular weight \[HMW\]) (C), and total adiponectin (D) between controls (C). Baseline and follow-up FEP (for VCAM-1: controls n=89, baseline n=99, follow-up=82; for E-selectin and adiponectin \[HMW\]: controls n=80, baseline n=84, follow-up=82; for total adiponectin: controls n=40, baseline n=44, follow-up=47). Two-tailed nonparametric Mann-Whitney U test was used.](pyx11001){#F1}

HMW and total adiponectin plasma levels were markedly lower in the follow-up group compared with both control and baseline groups, with no differences found between them ([Table 2](#T2){ref-type="table"}; [Figure 1C-D](#F1){ref-type="fig"}).

In summary, we found opposite alterations to the levels of the CV risk factors VCAM-1 and E-selectin in FEP baseline conditions compared with control. These alterations were no longer present in the FEP follow-up group. In the case of the protective factor adiponectin, its HMW and total plasma levels were lower at both pathological time points studied.

Effects of Demographic and Clinical Features on Altered Metabolic and CV Parameters in FEP Baseline and Follow-Up Groups {#s16}
------------------------------------------------------------------------------------------------------------------------

Our next goal was to evaluate through ANCOVA the possible influence of selected demographic and clinical characteristics only on the significant alterations observed by bivariate analysis in general metabolic and CV risk factors and novel CV risk/protective parameters in control and FEP subjects.

When comparing control and FEP baseline groups, all the alterations previously found in the bivariate analysis remained significant (BMI, E-Selectin, triglyceride, and HDL cholesterol levels and abdominal perimeter) except for the effect observed in VCAM-1 levels (see [supplemental Table 1A](#sup1){ref-type="supplementary-material"}). In addition, BMI was directly affected by gender (higher in males) and the existence of familiar CV clinical record ([supplemental Table 1A](#sup1){ref-type="supplementary-material"}). Triglyceride levels were also directly related to age and cotinine levels (tobacco consumption) in plasma ([supplemental Table 1A](#sup1){ref-type="supplementary-material"}). Finally, abdominal perimeter was directly related to gender (higher in males), age, and familiar CV clinical record ([supplemental Table 1A](#sup1){ref-type="supplementary-material"}).

Next, when control and FEP follow-up groups were compared, all the effects remained significant (BMI, HMW and total adiponectin, glycosylated hemoglobin, triglyceride and HDL cholesterol levels, and abdominal perimeter) ([supplemental Table 1B](#sup1){ref-type="supplementary-material"}). Furthermore, BMI was again affected by gender (higher in males) and also by age ([supplemental Table 1B](#sup1){ref-type="supplementary-material"}). HMW adiponectin levels were also related to gender and age ([supplemental Table 1B](#sup1){ref-type="supplementary-material"}). Triglycerides and HDL cholesterol were affected by age and gender, respectively and, finally, abdominal perimeter positively corelated both with gender and age ([supplemental Table 1B](#sup1){ref-type="supplementary-material"}).

Finally, when FEP baseline and follow-up groups were compared, the analysis made was slightly different, including the effects of very relevant clinical variables such as the GAF score, DDD of antipsychotic medication, and DUP (see [supplemental Table 1C](#sup1){ref-type="supplementary-material"}). The effects observed on E-selectin levels remained unaffected for all demographic and clinical factors studied ([supplemental Table 1C](#sup1){ref-type="supplementary-material"}). Adiponectin alterations were affected by gender (HMW type) and age (total), and, finally, glycosylated hemoglobin alterations were directly related to the existence of familiar CV clinical record ([supplemental Table 1C](#sup1){ref-type="supplementary-material"}).

To further investigative the significant alterations observed between baseline and follow-up FEP groups, we carried out a complementary regression model that analyzed the change of each biological marker (from baseline to the follow-up point) depending on the other selected variables. In this approach, we also checked the putative effects of the use of the specific antipsychotic drugs clozapine and olanzapine, due to their remarkable capacity to produce metabolic/CV alterations from the time of their prescription, as occurred in our conditions.

Using this approach, the difference in total antipsychotic equivalents was inversely related to the difference in E-selectin plasma levels between both time points studied (for each DDD unit increased during this period, E-selectin decreased 7.575 units during follow-up, after controlling for the effect of the increase in the other explanatory variables; see [Table 3](#T3){ref-type="table"}). In addition, the difference in the GAF score was also inversely related to the difference in both types of adiponectin (for each GAF scale unit increased during this period, HMW and total adiponectin levels decreased 0.057 units and 0.069 units, respectively) ([Table 3](#T3){ref-type="table"}). The total adiponectin difference between baseline and follow-up was affected by gender ([Table 3](#T3){ref-type="table"}). The difference in glycosylated hemoglobin levels was also inversely related to the GAF score between both time-frames studied (for each GAF scale unit increased during this period, glycosylated hemoglobin levels decreased 0.011 units) ([Table 3](#T3){ref-type="table"}). No specific effects of clozapine and olanzapine use on the parameters tested were found ([Table 3](#T3){ref-type="table"}).

###### 

Change of each biological marker (from baseline to the follow-up point) depending on selected demographic and clinical variables. Multiple linear regression analysis. Abbreviations: ß, linear regression coefficient; SE, standard error; CI, Confidence interval; OL, over limit; LL, Lower limit; BMI, body mass index; DDD, defined daily dose of antipsychotic chlorpromazine equivalents; DUBM, number of days elapsed between the onset of the FEP and blood samplings; DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale. The bold values in the table represents the values reaching statistical significance (P\<.05).

  N=53                    E-SELECTIN                                                                 
  ----------------------- -------------------------- ---------- -------- ------------- ------------- ------
  Gender (ref Female)     1111,603                   1894,739   ,587     -2714,900     4938,107      ,561
  Age                     306,990                    162,144    1,893    -20,466       634,446       ,065
  Cardiovascular record   -887,788                   7850,027   -,113    -16741,239    14965,663     ,911
  Lithium                 439,704                    3230,983   ,136     -6085,399     6964,806      ,892
  Antipsychotic DDD       -7,575                     3,347      -2,263   -14,334       -,816         ,029
  GAF                     -51,375                    79,835     -0,644   -212,604      109,854       ,523
  Cannabis consume        36,459                     52,865     ,690     -70,305       143,223       ,494
  Cotinin consume         -11,371                    11,689     -,973    -34,978       12,236        ,336
  DUBM                    7,477                      2,708      2,761    2,008         12,945        ,009
  DUP                     11,219                     12,173     0,922    -13,365       35,802        ,362
  Olanzapine+Clozapine    -2649,334                  2501,065   -1,059   -7700,337     2401,669      ,296
                          ADIPONECTIN HMW                                                            
  N=56                    B                          SE         t        CI 95% (OL)   CI 95% (LL)   p
  Gender (ref Female)     -,036                      ,618       -,059    -1,281        1,209         ,953
  Age                     -,021                      ,050       -,425    -,122         ,080          ,673
  Cardiovascular record   -0,904                     1,638      -,552    -4,204        2,396         ,584
  Lithium                 -,113                      1,027      -,110    -2,183        1,957         ,913
  Antipsychotic DDD       ,001                       ,001       1,018    -,001         ,003          ,314
  GAF                     -,057                      ,025       -2,272   -,108         -,006         ,028
  Cannabis consume        -,013                      ,016       -,826    -,044         ,018          ,413
  Cotinin consume         ,000                       ,004       ,112     -,007         ,008          ,911
  DUBM                    ,000                       ,001       -,238    -,002         ,002          ,813
  DUP                     -0,004                     0,004      -0,972   -0,012        0,004         ,336
  Olanzapine+Clozapine    0,428                      0,777      0,551    -1,138        1,994         ,584
                          ADIPONECTIN TOTAL                                                          
  N=24                    B                          SE         t        CI 95% (OL)   CI 95% (LL)   p
  Gender (ref Female)     2,201                      ,557       3,949    0,997         3,404         ,002
  Age                     ,094                       ,048       1,967    -,009         ,196          ,071
  Cardiovascular record   1,967                      1,325      1,485    -0,895        4,829         ,161
  Antipsychotic DDD       -,001                      ,002       -,781    -,005         ,002          ,449
  GAF                     -,069                      ,025       -2,800   -,123         -,016         ,015
  Cannabis consume        ,021                       ,025       ,842     -,033         ,076          ,415
  Cotinin consume         -,003                      ,006       -,507    -,015         ,009          ,621
  DUBM                    ,003                       ,001       2,504    ,000          ,005          ,026
  DUP                     0,006                      0,003      1,832    -0,001        0,013         ,090
  Olanzapine+Clozapine    0,288                      1,410      0,205    -2,757        3,333         ,841
                          GLYCOSYLATED HEMOGLOBLIN                                                   
  N=52                    B                          SE         t        CI 95% (OL)   CI 95% (LL)   p
  Gender (ref Female)     -,046                      ,100       -,465    -0,248        0,155         ,644
  Age                     ,003                       ,009       ,346     -,015         ,021          ,731
  Cardiovascular record   0,072                      0,286      ,252     -0,505        0,650         ,802
  Lithium                 -,205                      0,173      -1,187   -0,555        0,144         ,242
  Antipsychotic DDD       ,000                       ,000       -1,228   -,001         ,000          ,227
  GAF                     -,011                      ,004       -2,883   -,019         -,003         ,006
  Cannabis consume        -,003                      ,003       -1,053   -,009         ,003          ,299
  Cotinin consume         ,001                       ,001       ,793     -,001         ,002          ,432
  DUBM                    ,000                       ,000       ,732     ,000          ,000          ,469
  DUP                     0,000                      0,001      0,124    -0,002        0,002         ,902
  Olanzapine+Clozapine    -0,105                     0,124      -0,849   -0,356        0,145         ,401

Relationship between Pro-/Antiinflammatory Mediators and Altered Metabolic and CV Parameters in FEP Baseline and Follow-Up Groups {#s17}
---------------------------------------------------------------------------------------------------------------------------------

The overactivation of the inflammatory response has been related to an increased risk of developing metabolic and CV alterations. We previously reported a systemic pro-/antiinflammatory dysregulation in our FEP baseline and follow-up groups ([@CIT0019], [@CIT0020]). Considering this background, we applied the Pearson correlation analysis, trying to evaluate whether this inflammatory imbalance could be somehow affecting the metabolic and CV alterations found in FEP baseline and follow-up groups.

In this way, plasma levels of the proinflammatory mediator prostaglandin E~2~ directly correlated with E-selectin levels both in control and FEP baseline groups ([Table 4](#T4){ref-type="table"}). In addition, the activity of the proinflammatory nuclear factor κB (NFκB) in peripheral blood mononuclear cells directly correlated with both adiponectin HMW and total levels only in the FEP follow-up group ([Table 4](#T4){ref-type="table"}).

###### 

Relationship between cardiovascular and metabolic risk and protection factors and systemic pro/anti-inflammatory mediators. Multiple linear regression analysis. The bold values in the table represents the values reaching statistical significance (P\<.05).

  Control                               NFκB Act   COX2 WB   PGE~2~   iNOS WB   TBARS   PPARy Act   PPARy WB   15d-PGJ~2~   IκBα WB
  ----------------------- ------------- ---------- --------- -------- --------- ------- ----------- ---------- ------------ ---------
  VCAM-1                  Sig (Bilat)   0,118      0,204     0,131    0,564     0,866   0,742       0,041      0,766        0,126
  N                       67            130        150       131      149       124     28          150        131          
  Pearson's Coefficient   -0,13         -0,04      0,25      -0,07    0,12      -0,06   -0,43       -0,11      0,00         
  E-Selectin              Sig (Bilat)   0,310      0,654     0,003    0,456     0,145   0,487       0,023      0,182        0,997
  N                       66            126        146       127      145       120     28          146        127          
  Pearson's Coefficient   -0,15         -0,07      -0,09     -0,04    0,04      0,11    0,20        -0,06      -0,05        
  Adiponectin HMW         Sig (Bilat)   0,221      0,459     0,289    0,658     0,609   0,221       0,304      0,491        0,547
  N                       67            123        141       124      140       117     28          141        124          
  Pearson's Coefficient   -0,38         -0,11      -0,02     -0,14    0,11      0,11    0,13        -0,08      0,05         
  Adiponectin total       Sig (Bilat)   0,074      0,407     0,869    0,282     0,379   0,435       0,729      0,495        0,691
  N                       23            59         69        60       68        53      10          69         60           
  FEP's Baseline                        NFκB Act   COX2 WB   PGE~2~   INOS WB   TBARS   PPARy Act   PPARy WB   15d-PGJ~2~   IκBα WB
  Pearson's Coefficient   -0,23         -0,11      0,01      0,14     -0,06     -0,07   0,12        0,06       -0,22        
  VCAM-1                  Sig (Bilat)   0,184      0,398     0,947    0,300     0,624   0,642       0,708      0,625        0,100
  N                       34            58         67        59       66        51      12          67         59           
  Pearson's Coefficient   -0,21         -0,06      0,27      -0,07    0,05      0,17    -0,64       -0,15      0,01         
  E-Selectin              Sig (Bilat)   0,247      0,673     0,030    0,593     0,671   0,242       0,026      0,233        0,957
  N                       33            55         64        56       63        48      12          64         56           
  Pearson's Coefficient   -0,26         -0,20      -0,15     0,01     0,21      0,35    0,26        -0,11      -0,07        
  Adiponectin HMW         Sig (Bilat)   0,143      0,131     0,234    0,955     0,089   0,011       0,406      0,380        0,597
  N                       34            58         67        59       66        51      12          67         59           
  Pearson's Coefficient   -0,35         -0,21      -0,17     -0,10    0,23      0,61    0,65        -0,24      -0,01        
  Adiponectin total       Sig (Bilat)   0,197      0,284     0,343    0,593     0,205   0,003       0,351      0,175        0,959
  N                       15            29         34        30       33        22      4           34         30           
  FEP's Follow-up                       NFκB Act   COX2 WB   PGE~2~   INOS WB   TBARS   PPARy Act   PPARy WB   15d-PGJ~2~   IκBα WB
  Pearson's Coefficient   -0,01         -0,07      0,06      0,08     0,03      0,16    -0,24       -0,10      -0,15        
  VCAM-1                  Sig (Bilat)   0,907      0,518     0,602    0,500     0,767   0,226       0,435      0,413        0,233
  N                       81            80         81        80       81        56      13          73         62           
  Pearson's Coefficient   -0,21         -0,08      0,20      0,07     0,18      0,13    -0,42       -0,14      0,05         
  E-Selectin              Sig (Bilat)   0,063      0,459     0,072    0,564     0,101   0,328       0,152      0,242        0,690
  N                       81            80         81        80       81        56      13          73         62           
  Pearson's Coefficient   0,34          -0,08      -0,16     -0,02    0,10      -0,07   -0,04       0,07       -0,19        
  Adiponectin HMW         Sig (Bilat)   0,002      0,493     0,161    0,875     0,363   0,603       0,896      0,579        0,140
  N                       81            80         81        80       81        56      13          73         62           
  Pearson's Coefficient   0,35          -0,13      -0,13     0,07     0,10      0,06    0,49        -0,30      0,00         
  Adiponectin total       Sig (Bilat)   0,018      0,389     0,375    0,662     0,527   0,793       0,404      0,065        0,991
  N                       46            45         46        45       46        25      5           38         31           

The complementary analysis of the antiinflammatory mediators showed that the protein expression of the antiinflammatory nuclear peroxisome proliferator-activated receptor γ (PPARγ) in peripheral blood mononuclear cells negatively correlated with E-selectin levels and positively with VCAM-1 levels in control conditions ([Table 4](#T4){ref-type="table"}). Furthermore, in FEP baseline conditions, the protein levels PPARγ negatively correlated with E-selectin and PPARγ activity directly correlated with total and HMW adiponectin ([Table 4](#T4){ref-type="table"}).

Discussion {#s18}
==========

In this 6-month follow-up study with FEP subjects, we found specific alterations in the levels of classical and novel CV risk/protection biomarkers at the different time points analyzed. The complementary statistical approach made, considering the net difference between the values obtained at both temporal points studied for each parameter as dependent variables, allowed us to find an inverse relationship between the difference in total antipsychotic equivalents and the difference in E-Selectin plasma levels. In addition, the difference in GAF scores was also related to the difference in HMW and total adiponectin.

Finally, we also analyzed the possible relationship between CV risk/protective factor and pro-/antiinflammatory mediators. E-selectin levels were related to the levels of the proinflammatory mediator prostaglandin E~2~ both in control and FEP baseline groups. NFκB activity directly correlated with both HMW and total adiponectin levels only in the FEP follow-up group. In the case of antiinflammatory mediators, the protein levels PPARγ negatively correlated with E-selectin and PPARγ activity directly correlated with total adiponectin in the FEP baseline group.

Patients with chronic SZ present an increased susceptibility for suffering cardiac complications and even sudden cardiac death than the general population ([@CIT0027]); consequently, one of the fields of research is the study of CV risk and protection biomarkers, not only in full-blown SZ but also in earlier clinical manifestations and even in the prodromal phase. It is worth mentioning that the levels of all classical risk metabolic and CV factors studied in our cohort of FEP patients were in the normal range for subjects with a mean age of approximately 25 years, although we found some concomitant significant differences between groups that taken as a whole, could anticipate possible deleterious consequences in the physical condition of the FEP patients included in our study. The use of ratios between triglycerides, HDL and low density lipoprotein cholesterol to identify insulin resistance early in FEP patients of different gender is an interesting approach to explore in future studies ([@CIT0043]).

We have described a state in our cohort of FEP baseline subjects characterized by increased triglycerides and abdominal perimeter and decreased HDL cholesterol levels compared with control subjects. These alterations were also found in the follow-up group, and, in addition, FEP follow-up patients showed increased levels of glycosylated hemoglobin compared with both control and FEP basal groups. In this way, glycosylated hemoglobin could be considered a state biomarker, as the other trait biomarkers in our experimental conditions.

Previous studies identified the increased levels of glycosylated hemoglobin in plasma as a biomarker of poor control of blood glucose levels associated with CV alterations in FEP subjects with negative results ([@CIT0040]), although other glucose-metabolism related measures suggested, at least in one of the studies, that drug-naïve FEP subjects were more insulin resistant compared with matched controls ([@CIT0039]). A recent meta-analysis corroborated that glycosylated hemoglobin levels were not altered in FEP patients compared with controls; however, other glucose metabolism-related parameters were clearly affected, suggesting an early impairment in this system ([@CIT0041]). In chronic SZ, the increase in plasma glycosylated hemoglobin levels is well described ([@CIT0004]). In addition to these results, the inverse relationship between the GAF score and glycosylated hemoglobin plasma levels found with our regression models supports the idea suggested by some authors that routine testing of glycosylated hemoglobin could be helpful for early detection of diabetes in psychotic inpatients and its relationship to symptomatology ([@CIT0026]; [@CIT0048]; [@CIT0032]).

Regarding the CV risk factors studied, the effects observed on E-selectin are the most relevant, because our multiple linear regression analysis suggested that antipsychotic medication from baseline to follow-up groups could be related to the restored levels of E-selectin observed in FEP follow-up subjects. In previous longitudinal studies, there is some controversy: FEP subjects treated for 24 weeks with antipsychotics showed increased levels of E-selectin compared with the onset of treatment ([@CIT0023]), but in FEP subjects under antipsychotic medication for 3 months, patients treated with perphenazine, risperidone, and ziprasidone showed decreased levels of E-selectin in plasma compared with the baseline group ([@CIT0031]). It is worth mentioning that, in agreement with our report, patients treated with olanzapine or quetiapine did not present decreased levels of E-selectin in the 3-month follow-up, suggesting that each antipsychotic drug could be differentially affecting endothelial dysfunction and inflammation in pathological conditions.

The decreased levels of the CV protective factor adiponectin in the plasma of FEP follow-up patients compared with both control and FEP baseline groups also deserve further discussion. As in the case of E-selectin, some contradictory results have been reported. One study agreed with ours showing decreased levels of adiponectin in plasma samples of FEP subjects under antipsychotic medication for 24 weeks compared with the onset of treatment ([@CIT0023]). However, high levels in drug-naive FEP patients ([@CIT0047]) or no changes on adiponectin levels after 1 year of treatment with antipsychotics in drug-naive FEP patients ([@CIT0037]) have also been reported. A recent meta-analysis reported that subjects with SZ may not have lower levels of adiponectin than controls, but the specific treatment with olanzapine decreased adiponectin levels compared with other antipsychotics ([@CIT0005]). However, the results derived from our statistical approach did not support a specific effect of olanzapine or clozapine on the observed reduced levels of adiponectin between FEP baseline and follow-up groups.

To our knowledge, there are no studies evaluating the association between adiponectin levels and GAF score in psychotic patients. Our results are contra-intuitive, taking into account that adiponectin is accepted as a protective mediator. It is worth mentioning that our patients presented improved symptomatology measured by several clinical scales (GAF included) in the follow-up group compared with the baseline group. Thus, our results could suggest a relationship between adiponectin and global functioning, at least in early FEP, but its nature as well as the putative effects of other confounding factors needs to be further corroborated in future studies.

Finally, we took advantage of previous studies evaluating the state of pro-/antiinflammatory mediators in the same cohorts of FEP patients and controls used here ([@CIT0019], [@CIT0020]) to evaluate their putative relationship with VCAM-1, E-selectin, and adiponectin levels. We reported a direct correlation between NFκB activity and adiponectin only in the FEP follow-up group. The relationship between both factors is complex and the effects of adiponectin on NFκB depend on the isoform studied ([@CIT0002]). Interestingly, the isoform HMW (that was specifically measured in our study) activated nuclear factor NFκB-mediated gene expression of the E-selectin promoter in adipocytes in vitro ([@CIT0050]), an effect that could be related to the decrease in E-selectin observed in the FEP follow-up group. The activation of NFκB by HMW-adiponectin has been also described in vascular endothelial cells and monocyte/macrophage U937 cells ([@CIT0025]; [@CIT0049]). Indeed, further studies measuring the different adiponectin species are needed to elucidate the regulatory role of adiponectin on proinflammatory pathways, such as the one orchestrated by NFκB.

The correlation with antiinflammatory mediators only appeared with PPARγ and in the control and FEP baseline groups. The increased levels of E-selectin could be related to PPARγ expression downregulation as the inverse nature of their correlation suggests. PPARγ genetic or pharmacological positive modulation inhibited E-selectin expression in human endothelial cells both in vitro and in vivo ([@CIT0053]; [@CIT0022]), although some negative results also exist ([@CIT0035]).

In the FEP baseline group, total and HMW adiponectin were directly related to PPARγ activity. It is worth mentioning that adiponectin levels were not significantly different than in controls but were higher than in the FEP follow-up group. Whether a sustained level of adiponectin in the baseline group is related to PPARγ activity needs to be corroborated in future studies, but it has been recently described that adiponectin is induced by the pharmacological activation of PPARγ with the synthetic ligand rosiglitazone, affecting stress and negative emotion-related behaviors in rats submitted to a depression-like model ([@CIT0024]). Future studies with larger cohorts are needed to evaluate the interactions between inflammation and metabolic syndrome considered as a whole clinical entity for cardiovascular disturbances in FEP, as they have been already studied in SZ ([@CIT0028]) and other neuropsychiatric disorders ([@CIT0034]).

The present study presents several limitations: (1) most patients were under antipsychotic treatment for several months before blood extraction for biochemical determinations; (2) as it was a naturalistic study, not a randomized controlled trial, patients could be changing treatments during the follow-up period according to the clinician's choice; (3) all the participant sites are tertiary care centers linked to the Spanish network of translational research (CIBERSAM), so patient samples and therapeutic strategies may differ from those used in other areas; (4) a previous sample size calculation was not made. This calculation could have improved the design of the study and, in the case of a larger number of samples, we had probably found statistical differences in other variables, such as for example in E-selectin levels; (5) Control subjects were not followed 6 months after baseline as in case of FEP patients, and this limitation should be taken into account; and (6) there are statistically significant differences in BMI index between control and FEP patients. However, from a clinical point of view, all the subjects were in the range of normality following the BMI classical classification and thus, we consider that there are not significant clinical differences that could be decisively affecting the rest of results here reported.

In summary, we report here subtle but concomitant alterations of classical CV and metabolic risk factors in a cohort of FEP patients at the first onset of positive psychotic symptoms and at 6 months. Glycosylated hemoglobin emerged as a potentially relevant state biomarker for the diagnosis due to its relationship to the GAF score. In addition, among novel CV risk and protective factors analyzed, we concluded that alterations in plasma adiponectin levels could be a good clinical index, reflecting the degree of severity of the symptomatology. Our results support the need for integrating CV health care very early after the FEP.
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